Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATHE Alterity Therapeutics Limited

Pre-Market Trading 07-05 05:26:05 EDT

1.82

+0.01

+0.28%

High1.83	Low1.77	Vol8.46K
Open1.79	D1 Closing1.81	Amplitude3.31%
Mkt Cap15.87M	Tradable Cap14.39M	Total Shares8.74M
T/O15.25K	T/O Rate0.11%	Tradable Shares7.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ATHE","market":"US","secType":"STK","nameCN":"Alterity Therapeutics Limited","latestPrice":1.815,"timestamp":1720026000000,"preClose":1.81,"halted":0,"volume":8460,"delay":0,"floatShares":7928863,"shares":8741858,"eps":-2.042945,"marketStatus":"Pre-Market Trading","change":0.005,"latestTime":"07-05 05:26:05 EDT","open":1.7899,"high":1.83,"low":1.7701,"amount":15249.7791,"amplitude":0.033094,"askPrice":2.09,"askSize":100,"bidPrice":1.76,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.042945,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1720186200000},"marketStatusCode":1,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":1.79,"postHourTrading":{"tag":"盘后","latestPrice":1.815,"preClose":1.815,"latestTime":"16:26 EDT","volume":6,"amount":11.2499,"timestamp":1720038376523},"volumeRatio":2.4521520355827087},"requestUrl":"/m/hq/s/ATHE","defaultTab":"news","newsList":[{"id":"2431834172","title":"Alterity Therapeutics’ ATH434 Shows Treatment Promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2431834172","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431834172?lang=en_us&edition=fundamental","pubTime":"2024-04-29 18:58","pubTimestamp":1714388313,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) has released an update. Alterity Therapeutics has presented promising new data on ATH434, its lead drug candidate for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-ath434-shows-treatment-promise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-ath434-shows-treatment-promise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","LENZ"],"gpt_icon":0},{"id":"2428319553","title":"Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2428319553","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428319553?lang=en_us&edition=fundamental","pubTime":"2024-04-17 19:25","pubTimestamp":1713353100,"startTime":"0","endTime":"0","summary":"– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease –。Dr. Daniel Claassen, Professor of Neurology at Vanderbilt University Medical Center and coordinating investigator for the ATH434-201 Phase 2 study, commented, “The specialized neuroimaging and biomarker assessments evaluated and refined in the bioMUSE study were used to select and track patients in the Phase 2 study, making this program unique among current MSA clinical studies. It is vital to select study patients with a high degree of accuracy. The biomarkers being teste","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hHCqqEwtANkFUjQIhiWPHw--~B/aD01Njt3PTIyMjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e21f1e2bcd82d8889ade6f7680933e97","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hHCqqEwtANkFUjQIhiWPHw--~B/aD01Njt3PTIyMjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e21f1e2bcd82d8889ade6f7680933e97"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-parkinson-disease-multiple-112500087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","MSA","LU2125909916.SGD","LU2125909759.SGD","LU1169590202.USD","LU0053671581.USD","BK4107","ATH.AU","AFG","AAN","BK4139","LU1169589451.USD","ATHE","LU1923622291.USD","CSF","LENZ","PD","CSF.AU","BK4143","BK4023","LU1815336091.USD","BK7141","BK4178","LU0757428866.USD","BK4117"],"gpt_icon":0},{"id":"2427886162","title":"BSGM, ENLV and WISA among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2427886162","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2427886162?lang=en_us&edition=fundamental","pubTime":"2024-04-16 00:47","pubTimestamp":1713199631,"startTime":"0","endTime":"0","summary":"Gainers: Kaival Brands Innovations Group  +200%. Longeveron  +45%. Kuke Music Holding Ltd  +45%. Hub Cyber Security Ltd  +43%. Soligenix  +40%. Snap One Holdings Corp  +30%. Connexa Sports Technologies  +31%. Mobile-health Network Solutions  +26%. ProKidney Corp  +26%.  SilverSun Technologies  +25%.  Losers: Marinus Pharmaceuticals  -80%. Swvl Holdings Corp  -33%. Enlivex Therapeutics Ltd  -27%. WiSA Technologies  -21%. NeoVolta  -21%. Alterity Therapeutics Ltd  -20%. MSP Recovery  -19%. Biosig Technologies  -19%. Viracta Therapeutics  -19%. C3is  -19%.   More on Mid-day movers & stocks.  Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earnings data for BioSig Technologies, Inc. Financial information for BioSig Technologies, Inc.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4089705-bsgm-enlv-and-wisa-among-mid-day-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4021","HUBC","BK4139","LIFW","BK4078","MRNS","NEOV","BK4565","BK4196","ATHE","WISA","YYAI","BK4539","SNPO","BSGM","BK4571","CISS","ENLV","BK4141","BK4096","SWVL","LGVN","BK4082","VIRX","BK4510","SNGX","MNDR","KAVL","BK4159","BK4007","KUKE","PROK","SSNT","BK4022","BK4108","BK4230","BK4134","BK4097"],"gpt_icon":0},{"id":"2427077311","title":"NXPL, MGRM and OCX among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2427077311","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2427077311?lang=en_us&edition=fundamental","pubTime":"2024-04-15 20:21","pubTimestamp":1713183667,"startTime":"0","endTime":"0","summary":"Losers: Marinus Pharmaceuticals  -74% provides update on the phase 3 RAISE trial and reports preliminary first Quarter 2024 financial results. NextPlat Corp  -19%. Neumora Therapeutics  -17% as FDA puts Phase 1 schizophrenia study on hold. EZGO Technologies Ltd  -13%.  Monogram Orthopaedics  -10%. Alterity Therapeutics Ltd  -10%. Davis Commodities Ltd.  -8%. Polestar Automotive Holding  -7%. Torm Plc  -6%. CN Energy Group  -6%. Viracta Therapeutics  -6% announces positive topline Nana-val results from Stage 1 of the NAVAL-1 trial in patients. Oncocyte Corporation  -6%. Rallybio Corp  -6%. Rail Vision Ltd  -5%.   More on Pre-market losers & stocks.  OncoCyte Corporation  Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc.  Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. 2023 Q4 - Results - Earnings Call Presentation NextPlat announces proposed business combination with Progressive Care Oncocyte stock rallies 90% post-market on Bio-Rad partnership","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4089546-nxpl-mgrm-and-ocx-among-pre-market-losers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4090","PSNY","RVSN","MGRM","VIRX","BK4091","BK4144","BK4139","MRNS","BK4022","BK4089","BK4157","NXPL","OCX","DTCK","BK4099","ATHE","BK4588","BK4539","BK4102","EZGO","CNEY","BK4007","BK4082","NMRA","BK4585","TRMD","RLYB"],"gpt_icon":0},{"id":"2426844467","title":"CERS, GL and ATHE are among pre market gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2426844467","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2426844467?lang=en_us&edition=fundamental","pubTime":"2024-04-12 21:01","pubTimestamp":1712926895,"startTime":"0","endTime":"0","summary":"NextPlat  +69% FORM 10-K | Annual Report  Allarity Therapeutics  +36%. Zapata Computing Holdings  +23%. AMTD Digital  +21%. Globe Life  +13%. Hub Cyber Security  +15%. ECD Automotive Design  +13%. Oncocyte Corporation  +14% FY earnings call release  Lyell Immunopharma  +11%. Mobilicom  +11%. Coupang  +10% rallies after announcing sizable membership fee increase.  New Pacific Metals  +8%. NRX Pharmaceuticals  +7%. NextDecade Corporation  +7%. Cerus  +7%. Alterity Therapeutics  +6%. Mobile-health Network  +7%. Richtech Robotics  +6%. QT Imaging  +8%.   More on premarket gainers & stock  Cerus Corporation  Q4 2023 Earnings Call Transcript Globe Life Inc.  Q4 2023 Earnings Call Transcript Alterity Therapeutics receives A$3.9M research & development tax incentive refund Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients Seeking Alpha’s Quant Rating on Alterity Therapeutics","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4089240-cers-gl-and-athe-are-among-pre-market-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4122","NEWP","BK4089","LU1242518931.SGD","BK4020","NEXT","BK4134","CERS","BK4099","MOB.AU","BK4007","SG9999014005.SGD","ALLR","BK4161","BK4220","ECDA","BK4585","BK4548","NRXP","BK4168","CPNG","BK4198","BK4023","BK4210","BK4526","BK4505","BK4144","BK4162","ZPTA","ATHE","SG9999014013.SGD","LU0979878070.USD","BK4139","NXPL","SG9999014021.USD","GL","OCX","ALLR.AU","MOB","LU1242518857.USD","RR","BK4082","BK4588","HKD","QTI","LYEL","MNDR","HUBC","BK7056","BK4539"],"gpt_icon":0},{"id":"2426259334","title":"ATUS, ATHE and GRFS among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2426259334","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2426259334?lang=en_us&edition=fundamental","pubTime":"2024-04-11 20:16","pubTimestamp":1712837781,"startTime":"0","endTime":"0","summary":"More on pre-market losers stock  Grifols: Q4 Was Positive, Still Too Many Question Marks Altice USA: Recent Refinancing Buys Time But Challenges Remain Altice USA, Inc.  Q4 2023 Earnings Call Transcript Altice slips as Wells Fargo cuts estimates, downgrades amid fiber competition worries Alterity Therapeutics receives A$3.9M research & development tax incentive refund","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088876-atus-athe-and-grfs-among-pre-market-losers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["KMX","SILO","WNW","BK4095","BK4585","BK4167","PSQ",".IXIC","BK4588","BK4113","BK4139","SQQQ","BK4561","BK4100","QQQ","ICCT","BK4122","APVO","ATHE","GRFS","BK4539","MNQmain","QID","LOVE","CLRO","BK4020","BK4134","ATUS","NQmain","BK4202","TQQQ","HUBC","BK4214","INAB","QLD"],"gpt_icon":0},{"id":"2422610504","title":"Alterity Therapeutics receives A$3.9M research & development tax incentive refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2422610504","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422610504?lang=en_us&edition=fundamental","pubTime":"2024-03-26 23:11","pubTimestamp":1711465916,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  on Tuesday said it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive  Scheme. The cash refund relates to the cost of eligible research and development activities conducted during the financial year ended 30 June 2023.  These funds will be used to further Alterity’s Phase 2 clinical trials in MSA, ATH434-201 and ATH434-202, along with planning for a potential Phase 3 clinical trial in MSA, continuing discovery and research efforts in neurodegenerative diseases, including Parkinson’s Disease, and general working capital. ATHE is +0.6% to $1.7204. Source: Press Release    More on Alterity Therapeutics  Alterity Therapeutics drops on capital raise Seeking Alpha’s Quant Rating on Alterity Therapeutics Historical earnings data for Alterity Therapeutics Financial information for Alterity Therapeutics","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083797-alterity-therapeutics-receives-a39m-research-development-tax-incentive-refund","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ATHE","LENZ","BK4139","XJO.AU","XKO.AU","XAO.AU"],"gpt_icon":0},{"id":"2422611700","title":"Press Release: Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2422611700","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422611700?lang=en_us&edition=fundamental","pubTime":"2024-03-26 22:25","pubTimestamp":1711463100,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024  -- Alterity Therapeutics Limited  , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government's Research and Development Tax Incentive  Scheme.The cash refund relates to the cost of eligible research and development activities conducted during the financial year ended 30 June 2023, and represents the amount disclosed in the company's audited financial statements. These funds will be used to further Alterity's Phase 2 clinical trials in MSA, ATH434-201 and ATH434-202, along with planning for a potential Phase 3 clinical trial in MSA, continuing discovery and research efforts in neurodegenerative diseases, including Parkinson's Disease, and general working capital.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHE","ATH.AU","LU0053671581.USD","MSA","LU2125909759.SGD","BK4143","LU2125909916.SGD","LU1923622291.USD","BK7067","BK4139","XKO.AU","LENZ","XAO.AU","XJO.AU","LU0757428866.USD","LU1815336091.USD"],"gpt_icon":0},{"id":"2422907506","title":"Alterity Therapeutics Secures $3.9M R&D Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2422907506","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422907506?lang=en_us&edition=fundamental","pubTime":"2024-03-26 20:57","pubTimestamp":1711457855,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) has released an update. Alterity Therapeutics, a biotech firm advancing treatments for neurodegenerative diseases, has...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-secures-3-9m-rd-refund?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-secures-3-9m-rd-refund?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","LENZ"],"gpt_icon":0},{"id":"2413790562","title":"Alterity Therapeutics drops on capital raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2413790562","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2413790562?lang=en_us&edition=fundamental","pubTime":"2024-02-24 02:39","pubTimestamp":1708713582,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  traded sharply lower on Friday after the Australian biotech announced plans to raise A$3.25M  in gross proceeds via a placement of its ordinary shares to a group of institutional and individual investors. According to a regulatory filing, the company will issue ~855.3M of new shares in a transaction expected to occur on or about March 4, 2024. A free attaching option will also be available for every three new shares issued, subject to shareholder approval.  Alterity  has plans to use the proceeds to conduct its Phase 2 clinical trials, ATH434-201 and ATH434-202, for its lead asset, ATH434, in multiple system atrophy, a rare neurodegenerative disease. The additional capital will also help the company plan a Phase 3 clinical trial in MSA, conduct other R&D efforts, and fund general corporate purposes.    More on Alterity Therapeutics  Alterity jumps after promising data on Parkinson's candidate Seeking Alpha’s Quant Rating on Alterity Therapeutics Historical earnin","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4071275-alterity-stock-drops-capital-raise","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","ATHE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alteritytherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":-0.0692},{"period":"3month","weight":-0.0109},{"period":"6month","weight":-0.1519},{"period":"1year","weight":-0.3228},{"period":"ytd","weight":-0.2711}],"compareEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.0448},{"period":"3month","weight":0.0748},{"period":"6month","weight":0.1785},{"period":"1year","weight":0.2426},{"period":"ytd","weight":0.1602}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.081222},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.064525},{"month":3,"riseRate":0.409091,"avgChangeRate":0.005611},{"month":4,"riseRate":0.5,"avgChangeRate":-0.019094},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.055947},{"month":6,"riseRate":0.318182,"avgChangeRate":0.026025},{"month":7,"riseRate":0.590909,"avgChangeRate":0.094651},{"month":8,"riseRate":0.619048,"avgChangeRate":0.075459},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.031693},{"month":10,"riseRate":0.318182,"avgChangeRate":-0.071611},{"month":11,"riseRate":0.409091,"avgChangeRate":-0.027012},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.025252}],"exchange":"NASDAQ","name":"Alterity Therapeutics Limited","nameEN":"Alterity Therapeutics Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alterity Therapeutics Limited,ATHE,Alterity Therapeutics Limited股票,Alterity Therapeutics Limited股票老虎,Alterity Therapeutics Limited股票老虎国际,Alterity Therapeutics Limited行情,Alterity Therapeutics Limited股票行情,Alterity Therapeutics Limited股价,Alterity Therapeutics Limited股市,Alterity Therapeutics Limited股票价格,Alterity Therapeutics Limited股票交易,Alterity Therapeutics Limited股票购买,Alterity Therapeutics Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}